Non-viral gene therapy with ECD4-IG
Ended Project Grant Awarded Last action
- Award ID
- R56AI189343
- Recipient
-
Emmune Inc. UEI N65ZDYUGWAH8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,836,795
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Description
- Abstract
- We are developing non-viral gene therapy with ECD4-IG as a practical approach for suppressing HIV replication for a lifetime after a one-time intramuscular injection. The error-prone nature of reverse transcriptase, and the sequence plasticity of the HIV envelope glycoprotein (ENV), result in the rapid escape of neutralizing antibodies and daunting levels of global antigenic diversity. The antigenic diversity of HIV and ease of escape of antibody responses can be countered with ECD4-IG, which is an antibody-like therapeutic protein constructed from parts of HIV's primary receptor (CD4) and coreceptor (CCR5). ECD4-IG functions like a broadly-neutralizing antibody (bnab) in being able to neutralize virus infection and mediate effector functions, but cannot be escaped without HIV sacrificing its ability to bind its receptor and coreceptor. Here, we propose developing a non-viral gene therapy platform and its use to sustain therapeutically-effective plasma concentrations of ECD4-IG for potentially a lifetime after a single administration. We propose basic science experiments that will inform the development of this non-viral gene therapy platform, plus the development of approaches for enhancing the efficiency of gene transfer into skeletal muscle. The proposed studies build on our work with adeno-associated virus (AAV) vectors to establish a state of long-term viral remission where further treatment is not required to suppress plasma viral loads to levels that are undetectable using standard assays. We and others term such a state of long-term viral suppression, albeit one short of eradication, a 'functional cure.' the lifelong expression of therapeutic concentrations of ECD4-after a one-time intramuscular administration of a non-viral gene therapy vector is a feasible means of achieving a functional cure for HIV.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$2,207 | |
| Amendment | $919,501 | |
| Original award | $919,501 |
Quick answers
Who received award R56AI189343?
R56AI189343 was awarded to Emmune Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 17, 2025.
How much is award R56AI189343 worth?
$1,836,795 has been obligated on R56AI189343.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award